Apexigen Inc
Change company Symbol lookup
Select an option...
APGN Apexigen Inc
NSRGY Nestle SA
WE WeWork Inc
NOK Nokia Oyj
HLNE Hamilton Lane Inc
SAL Salisbury Bancorp Inc
MFON Mobivity Holdings Corp
XPEV Xpeng Inc
ENVX Enovix Corp
COGT Cogent Biosciences Inc
Go

Company profile

Apexigen, Inc., formerly Brookline Capital Acquisition Corp., is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology. It has a diversified pipeline of wholly owned and partnered assets leveraging its APXiMAB antibody discovery platform. The Company’s pipeline of immuno-oncology therapeutic candidates is led by sotigalimab, which is in Phase II clinical development, and also includes several preclinical stage immuno-oncology programs. The Company’s lead asset, sotigalimab, is a CD40 agonist with epitope specificity and Fc receptor engagement for optimal therapeutic effect. Its sotigalimab is used for the treatment of Melanoma (post PD-1), Esophageal/GEJ, Sarcoma, Rectal and Ovarian cancers. Its pipeline also includes APX601 and APX801. It has out-licensed five programs for the development of product candidates that were discovered using the APXiMAB platform.

Price
Delayed
$7.09
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 332 shares is on pace to be much lighter than APGN's 10-day average volume of 420,125 shares.

332

Unable to locate that news article. Back to news results

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.